Maplirpacept
Based on 1 Customer Validation
Maplirpacept (TTI-622; PF-07901801) is a fusion protein consisting of the CD47-binding domain of human SIRPα linked to the Fc region of human IgG4. Maplirpacept enhances phagocytosis by blocking CD47.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 97.73%
- CAS No.: 2631667-06-4
- Masse moléculaire:77.129 kDa
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Activité biologique
Fusion-SIRPA-IGHG4 Fc
Human
CD47
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
FPIA_[PROTEIN]2-FC
-
Immobilized CD47 Protein, Human (HEK293, HY-P72917) can bind Maplirpacept. The EC50 for this effect is 74.77 ng/mL.
Chemical Information
-
CAS No. 2631667-06-4
-
Appearance Liquid
-
Masse moléculaire 77.129 kDa
-
Color Colorless to light yellow
-
Synonyms
TTI-622; PF-07901801
-
Livraison
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
-
Fiche technique (255 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)